(Total Views: 350)
Posted On: 05/13/2019 11:30:27 AM
Post# of 72447
FDA's cancer drugs committee is anxious to approve new drugs.
But, Daiichi Sankyo "lost" the data for the 25th week of their clinical trial. FDA is not amused.
https://endpts.com/daiichi-sankyo-faces-fda-c...-drug-oks/
Quote:
[FDA's committee] has typically used some liberal assessments in reviewing new drugs, anxious to provide approvals in cases where docs want more options, or no drugs are currently approved .
But, Daiichi Sankyo "lost" the data for the 25th week of their clinical trial. FDA is not amused.
https://endpts.com/daiichi-sankyo-faces-fda-c...-drug-oks/
(1)
(0)
